TILTAN PHARMA

tiltan-pharma-logo

One of the major advances in cancer research over the past decade has been the realization that tumor growth is dependent on the tumor's ability to recruit blood vessels from the neighboring tissue. Angiogenesis, the process by which new blood vessels are formed, is a hallmark capability of cancer, critical for the development of all solid tumors. This property is the basis for anti-angiogenic therapy, a promising novel strategy for treatment of cancer.

#People #Website #More

TILTAN PHARMA

Industry:
Biotechnology Health Care Therapeutics

Founded:
2006-01-01

Address:
Jerusalem, Yerushalayim, Israel

Country:
Israel

Website Url:
http://www.tiltanpharma.com

Total Employee:
1+

Status:
Active

Contact:
97286473836

Email Addresses:
info@tiltanpharma.com

Total Funding:
1.5 M USD

Technology used in webpage:
Apache Euro Google Apps For Business Typekit GoDaddy Starfield Technologies Adobe Muse Adobe Creative Cloud WebFonts


Current Employees Featured

not_available_image

Dan Goldstaub
Dan Goldstaub COO @ Tiltan Pharma
COO

yigal-stav_image

Yigal Stav
Yigal Stav Co-Founder & CEO @ Tiltan Pharma
Co-Founder & CEO

Founder


yigal-stav_image

Yigal Stav

Official Site Inspections

http://www.tiltanpharma.com Semrush global rank: 6.11 M Semrush visits lastest month: 1.33 K

  • Host name: 67.89.153.160.host.secureserver.net
  • IP address: 160.153.89.67
  • Location: Scottsdale United States
  • Latitude: 33.6013
  • Longitude: -111.8867
  • Metro Code: 753
  • Timezone: America/Phoenix
  • Postal: 85260

Loading ...

More informations about "Tiltan Pharma"

Tiltan Pharma - Crunchbase Company Profile & Funding

Contact Email info@tiltanpharma.com Phone Number 97286473836 One of the major advances in cancer research over the past decade has been the realization that tumor growth is …See details»

Tiltan Pharma 2025 Company Profile: Valuation, Funding

Information on valuation, funding, cap tables, investors, and executives for Tiltan Pharma. Use the PitchBook Platform to explore the full profile.See details»

Tiltan Pharma Company Profile | Management and Employees List

Www.tiltanpharma.com . Contact Information. Headquarters. 1 1 Hi Tech Village Edmond Safra Campus Givat Ram, Jerusalem, Jerusalem, Israel +972 2-566-9411. Tiltan Pharma Profile and …See details»

Tiltan Pharma - Craft

Tiltan Pharma has 5 employees at their 1 location and $1.5 m in total funding,. See insights on Tiltan Pharma including office locations, competitors, revenue, financials, executives, …See details»

Wegis & Young: Buttonwillow, California, USA

The Wegis and Young families have been an instrumental part of California and Kern County agriculture as well as the community for well over 100 years. Our operation was born at the …See details»

Tiltan Pharma Overview | SignalHire Company Profile

Organization Website: tiltanpharma.com : Tiltan Pharma industries Biotech: Headquarters Location: 2-4 Hi-tech Village, Jerusalem, Jerusalem District, 91390 IL 2-4 Hi-tech Village, …See details»

Tiltan Pharma - Israeli Startup | Startup Nation Finder

Mar 19, 2012 Tiltan Pharma is a biopharmaceutical company that developed a proprietary anti-angiogenic and immune modulatory platform for the treatment of cancer.See details»

Tiltan Pharma - Overview, News & Similar companies - ZoomInfo

View Tiltan Pharma (www.tiltanpharma.com) location in Jerusalem, Israel , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»

Tiltan Pharma - 2025 Company Profile - Tracxn

Feb 25, 2025 Tiltan Pharma - Develops therapeutics for treatment of metastatic pancreatic cancer using combinatorial drug therapy technology. This company is not active anymore. …See details»

Tiltan Pharma - VentureRadar

Website: http://www.tiltanpharma.com/ Tiltan Pharma’s proprietary anti-cancer platform is based on a combination of agents that target different, non-overlapping ...See details»

Tiltan Pharma Ltd. (Tiltan Pharma Ltd.) - 药物管线_专利_临床试验_ …

TL-118 is an anti-angiogenic drug combination designed for the treatment of cancer. The investigational product Tl-118 comprises of four well-known active components.See details»

Tiltan Pharma - Golden

Tiltan Pharma is an oncology company. Overview Structured Data Issues Contributors Activity. ContentsSee details»

Tiltan Pharma - Products, Competitors, Financials, Employees ...

Tiltan Pharma Raises $1.5 Million. Feb 5, 2014. Kunshan RiboQuark Raises .5 Million for siRNA Projects Tiltan Pharma Ltd. today announced that it has raised $1.5 million for the completion …See details»

Tiltan Pharma CEO and Key Executive Team | Craft.co

Tiltan Pharma's Chief Operating Officer is Dan Goldstaub. Other executives include Osnat Ohne, Chief Operating Officer; Shmuel Rubinstein, Chairman, Former Chief Executive Officer and …See details»

Tiltan Pharma Ltd.:Company Profile & Technical …

Tiltan Pharma Ltd. is a company that provides Pharmacy and Therapeutics, Blood vessel, Cancer research and more. Tiltan Pharma Ltd. is headquartered in Israel .See details»

Tiltan Pharma | LinkedIn

Tiltan Pharma | ٦٤ من المتابعين على LinkedIn. Tiltan Pharma is a clinical stage biotechnology company focused on the development of novel and synergistic combinations of known drugs for the …See details»

Tiltan Pharma Culture | Comparably

Learn about Tiltan Pharma's culture, see what work's like, read reviews, and find job opportunities.See details»

Tiltan Pharma Financial Overview, Employee Count, and Competitors

+972 2-566-9411. Jerusalem, Jerusalem District. tiltanpharma.comSee details»

Tiltan Pharma Raises $1.5 Million – Integra Holdings

Jerusalem, Israel - February 5, 2014 - Tiltan Pharma Ltd. today announced that it has raised $1.5 million for the completion of its on-going Phase 2 clinical study of TL-118, an anti-angiogenic …See details»

Novartis receives third FDA approval for oral Fabhalta® (iptacopan ...

5 days ago Novartis receives third FDA approval for oral Fabhalta ® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G). Phase III study showed sustained …See details»